This company has been acquired
Opiant Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Opiant Pharmaceuticals Il CEO è Roger Crystal, nominato in Sep2009, e ha un mandato di 13.5 anni. la retribuzione annua totale è $ 1.48M, composta da 42.9% di stipendio e 57.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.64% delle azioni della società, per un valore di $ 695.26K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 6.8 anni.
Informazioni chiave
Roger Crystal
Amministratore delegato
US$1.5m
Compenso totale
| Percentuale dello stipendio del CEO | 42.9% |
| Mandato del CEO | 13.5yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 5.5yrs |
| Durata media del Consiglio di amministrazione | 6.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$635k | US$3m |
| Sep 30 2021 | n/a | n/a | US$2m |
| Jun 30 2021 | n/a | n/a | -US$1m |
| Mar 31 2021 | n/a | n/a | -US$3m |
| Dec 31 2020 | US$1m | US$610k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$108k |
| Jun 30 2020 | n/a | n/a | US$10m |
| Mar 31 2020 | n/a | n/a | US$12m |
| Dec 31 2019 | US$1m | US$592k | US$12m |
| Sep 30 2019 | n/a | n/a | US$988k |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$865k | US$574k | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$2m |
| Jun 30 2018 | n/a | n/a | -US$5m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | n/a | n/a | US$3m |
| Oct 31 2017 | n/a | n/a | US$2m |
| Jul 31 2017 | US$1m | US$568k | US$7m |
| Apr 30 2017 | n/a | n/a | US$6m |
| Jan 31 2017 | n/a | n/a | US$9m |
| Oct 31 2016 | n/a | n/a | US$3m |
| Jul 31 2016 | US$5m | US$616k | -US$8m |
Compensazione vs Mercato: La retribuzione totale di Roger ($USD 1.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 650.00K ).
Compensazione vs guadagni: La retribuzione di Roger è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Roger Crystal (46 yo)
13.5yrs
Mandato
US$1,477,846
Compensazione
Dr. Roger Crystal, M.D., has been an Independent Director of Mind Medicine (MindMed) Inc. since August 11, 2022. Dr. Crystal has been the Chief Executive Officer of Opiant Pharmaceuticals, Inc. since Septe...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 13.5yrs | US$1.48m | 0.64% $ 695.3k | |
| Chief Financial Officer | 5.5yrs | US$786.67k | 0.43% $ 464.9k | |
| Chief Scientific Officer | 6.1yrs | US$800.11k | 0.19% $ 202.6k | |
| Vice President of Communications & Investor Relations | no data | Nessun dato | Nessun dato | |
| EVP Corporate Development & General Counsel | 2.6yrs | Nessun dato | 0.34% $ 369.9k | |
| Chief Development Officer | no data | Nessun dato | 0.36% $ 387.2k | |
| Chief Commercial Officer | 1.7yrs | Nessun dato | 0.13% $ 137.7k |
5.5yrs
Durata media
57.5yo
Età media
Gestione esperta: Il team dirigenziale di OPNT è esperto e expertise (durata media dell'incarico 5.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 13.5yrs | US$1.48m | 0.64% $ 695.3k | |
| Independent Director | 12.3yrs | US$42.70k | 1.14% $ 1.2m | |
| Independent Director | 6.3yrs | US$113.70k | 0.20% $ 214.2k | |
| Independent Chairman | 4.4yrs | US$137.20k | 1.02% $ 1.1m | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.8yrs | US$109.70k | 0.50% $ 540.6k | |
| Chairwoman of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.8yrs | US$103.70k | 0.41% $ 440.7k | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato |
6.8yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di OPNT sono considerati esperti (durata media dell'incarico 6.8 anni).